Rapid advances in cancer immunotherapy offer novel treatment opportunities for patients. It also creates new challenges for clinicians aiming to offer the most suitable treatment based on a precise diagnosis and an informed decision-making process.
To stimulate the exchange with international colleagues and to learn from experiences gained in other Cancer Centers, Oslo Cancer Cluster is starting a new I-O Educational Meeting Series tailored for Norwegian clinicians and translational researchers. This meeting series is a continuation of the I-O Educational Seminars established in 2015.
Clinicians and translational researchers are invited to attend this meeting to address different aspects along the treatment course – from diagnosis to treatment and follow-up of cancer patients. Participants will have the opportunity to meet with international experts presenting recent progress and clinical implications.
Due to limited seating capacity, all seating on-site is reserved for clinicians and translational researchers (Please register by completing the form below).
All other parties are invited to the join this event online via streaming (There is no need to register online if you would like to join via streaming. Please email firstname.lastname@example.org for more information).
|Moderator||Anna Winge-Main, Senior Consultant, Oslo University Hospital|
|15:30–16:00||Registration and Refreshments|
|16:00–16:05||Opening and Welcome by the Moderator|
|16:05–17:00||Biomarker-driven Strategies and Personalised Medicine in Lung Cancer*
Keith Kerr, Professor, Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary
(Session: 35-40 minute talk followed by a lung cancer case to open the Q&A.)
|17:10–18:00||Melanoma: Existing and Emerging Biomarkers and Predictors of Response*
Henrik Schmidt, Associate Professor, Head of Clinical Research Unit, Department of Oncology, Aarhus University Hospital
(Session: 30-35 minute talk followed by a melanoma case to open the Q&A/includes patient involvement based on a recent study on patient-reported outcomes in cancer consultations.)
Participants are welcome to stay for additional exchanges.